refractory anemia with excess blasts (RAEB)
Jump to navigation
Jump to search
Epidemiology
- 23% of cases of myelodysplastic syndrome
Pathology
- circulating blasts < 5%
- bone marrow blasts 5-20%
- < 15% ringed sideroblasts in marrow
- no Auer rods
Management
- prognosis:
- 11-50% transformation to acute leukemia (AML)
- survival 7-15 months (mean 9 months)
More general terms
References
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 677-78